Pharmaceutical company Moderna says it is scaling down its investments in late-stage vaccine trials amid growing opposition ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...

The Cleburne Railroaders officially unveiled their refreshed logo and brand identity Thursday at La Moderna Field, marking ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

Check out the companies making headlines in midday trading. Fortinet — Shares jumped more than 7% after TD Cowen upgraded the cybersecurity stock to buy from hold, saying rising memory prices won't ...

The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower ...

You cannot make a return on investment if you don’t have access to the U.S. market," CEO Stéphane Bancel said. In other news, the chairman of the Advisory Committee on Immunization Practices suggested ...

Intel shares slip ahead of the chip maker’s fourth-quarter earnings, due out after the close of trading Thursday.

Dr. Mani Foroohar, Leerink Partners, joins 'Closing Bell Overtime' to talk Moderna prices climbing on positive drug trial.

Moderna does not plan to ‌invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S.

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...